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ABSTRACT
In amousemodel, inflammatory cytokines play a primary role in the development of acute graft-versus-host dis-
ease (aGVHD).Here, we retrospectively evaluated whether the preengraftment C-reactive protein (CRP) value,
which is used as a surrogate marker of inflammation, could predict posttransplant complications including
GVHD. Two hundred twenty-four adult patients (median age, 47 years; range: 18-68 years) underwent conven-
tional stem cell transplantation (CST, n5 105) or reduced-intensity stem cell transplantation (RIST, n 5 119).
Patients were categorized according to the maximum CRP value during neutropenia: the ‘‘low-CRP’’ group
(CRP\ 15 mg/dL, n 5 157) and the ‘‘high-CRP’’ group (CRP $ 15 mg/dL, n 5 67). The incidence of docu-
mented infections during neutropenia was higher in the high-CRP group (34% versus 17%, P 5 .004). When
patients with proven infections were excluded, the CRP value was significantly lower after RIST than after
CST (P 5 .017) or after related than after unrelated transplantation (P\ .001). A multivariate analysis showed
that male sex, unrelated donor, and HLA-mismatched donor were associated with high CRP values. The high-
CRP group developed significantly more grade II-IV aGVHD (P 5 .01) and nonrelapse mortality (NRM) (P\
.001), but less relapse (P 5 .02). The present findings suggest that the CRP value may reflect the net degree
of tissue damage because of the conditioning regimen, infection, and allogeneic immune reactions, all of which
lead to subsequent aGVHD and NRM.
 2008 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is associatedwithhigh treatment-relatedmor-
tality (TRM) because of acute graft-versus-host disease
(aGVHD) and infections [1,2]. Inflammatory cyto-
kines, for example, tumor necrosis factor-a (TNF-a),
interleukin-1 (IL-1), and IL-6 [3-11], are produced fol-
lowing conditioning and play a primary role in activat-
ing T cells, leading to GVHD and resultant target
tissue destruction [12,13]. An acute-phase protein,
C-reactive protein (CRP), is produced by hepatocytes
downstream of IL-6 [14] and is widely used as a reliable510surrogate marker of infectious diseases [15-19]. This
process is further stimulated by other cytokines in-
cluding TNF-a [12,13]. After allogeneic HSCT, the
elevation of CRPwas observed with infectious compli-
cations, but not in uncomplicated aGVHD [8,20]. On
the other hand, elevation of CRP has been shown to
be associated with TRM [21-24]. Nevertheless, these
previous studies adopted the sporadic measurement
of CRP and mostly focused on patients undergoing
conventional HSCT (CST) with a myeloablative regi-
men. It has been hypothesized that recently developed
reduced-intensity HSCT (RIST) decreases regimen-
related toxicities and, hence, may reduce inflammation
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reaction to induce GVHD and nonrelapse mortality
(NRM).
In this study, the correlation between the preen-
graftment CRP value and subsequent clinical events
was analyzed to test whether high CRP reflected the
degree of tissue damage because of the conditioning
regimen, infections, and allogeneic immune reactions
and/or inflammation, all of which could contribute
to subsequent aGVHD and NRM.
MATERIALS AND METHODS
Patient Characteristics
The data from a cohort of 224 consecutive adult
patients with hematologic malignancies, who were
treated between January 2002 and July 2006 at the
National Cancer Center Hospital (NCCH, Tokyo,
Japan), were reviewed retrospectively. Patients who
developed graft failure or who had previous allogeneic
transplantation were excluded. Their characteristics
are listed in Table 1. The median age of the patients
was 47 years (range: 18-68 years), and their diagnosis
included acute myeloid leukemia (AML, n5 94), acute
lymphoblastic leukemia (ALL, n 5 23), non-Hodgkin
lymphoma (NHL, n5 62), myelodysplastic syndrome
(MDS, n 5 27) and chronic myeloid leukemia (CML,
n 5 12). Standard risk included acute leukemia in first
complete remission, chronic leukemia in the first
chronic phase, MDS in refractory anemia, and NHL
in complete remission, with the rest of the patients cat-
egorized as a high-risk group. Stem cell sources used
for transplantation included bone marrow (BM, n 5
108), peripheral blood stem cells (PBSC, n 5 98) and
cord blood cells (CB, n 5 18). One-hundred five pa-
tients received a CST regimen including total-body
irridiation (TBI)-based (n 5 50) and non-TBI-based
busulfan-containing regimens (n 5 55), whereas 119
patients received a RIST regimen including fludara-
bine or cladribine plus busulfan or melphalan (Table
1). CMV serostatus was positive in 157 patients and
negative in 67 patients. The median age of the patients
was 49 years in the high-CRP group (range: 19-67) and
47 years in the low-CRP group (range: 18- 68). Writ-
ten informed consent was obtained according to the
Declaration of Helsinki.
Transplantation Procedures
GVHD prophylaxis included cyclosporine- (n 5
174) and tacrolimus-based regimens (n 5 50), with
an additional short course of methotrexate (MTX) in
165 patients. Granulocyte colony-stimulating factor
(G-CSF) was administered in all patients from day
16 of transplantation until engraftment was con-
firmed. Most patients received ciprofloxacin (200 mg
orally 3 times daily) for bacterial prophylaxis until neu-
trophil engraftment. Fluconazole (100 mg once daily)was administered for fungal prophylaxis. Low-dose
acyclovir was given for prophylaxis against herpes sim-
plex virus and varicella zoster virus until the cessation
of immunosuppressive agents. Prophylaxis against
Pneumocystis jiroveci infection was provided with
trimethoprim-sulfamethoxazole (400 mg of sulfame-
thoxazole once daily) from the first day of conditioning
to day 23 of transplantation, and from day 128 until
day 1180 or the discontinuation of immunosuppres-
sive agents. Patients with fever during the neutropenic
period were treated with cefepime, and additional
agents including vancomycin and aminoglycosides,
and amphotericin B were given as clinically indicated.
Neutrophil engraftment was defined as the first of 3
consecutive days after transplantation that the absolute
neutrophil count exceeded 0.5  109/L. In our insti-
tute, the CRP level was serially measured as part of
our routine checkup at least 3 times a week. Hence,
all serially admitted patients were subjected to this
analysis. Every patient had started CRP measurement
Table 1. Patients’ Characteristics
N (%)/ Median
Variable
Low CRP
Group CRP
\ 15 mg/dL
n 5 157
High CRP
Group CRP
$ 15 mg/dL
n 5 67 P Value
Age (year) 47 (18-68) 49 (19-67) .85
\40 53 (34) 26 (39)
$40 104 (66) 41 (61) .47
Patient sex
Male 84 (54) 48 (72)
Female 73 (46) 19 (28) .01
Donor sex
Male 81 (52) 30 (45)
Female 76 (48) 37 (55) .35
CMV serostatus
Positive 140 (89) 64 (96)
Negative 17 (11) 3 (4) .20
Disease risk
Standard 35 (22) 17 (25)
High 122 (78) 50 (75) .62
Conditioning
CST 72 (47) 33 (50)
RIST 85 (53) 34 (50) .64
GVHD prophylaxis
Cyclosporin-based 122 (78) 52 (78)
Tacrolimus-based 35 (22) 15 (22) .99
Short term MTX (1) 107 (68) 58 (87) .004
Relation to donor
Related 94 (60) 13 (19)
Unrelated 63 (40) 54 (81) \.001
Stem cell source
Bone marrow 63 (40) 45 (67)
PBSC 87 (55) 11 (16)
Cord blood 7 (5) 11 (16) \.001
CRP indicates C-reactive protein; CMV, cytomegalovirus; CST,
conventional stem cell transplantation; RIST, reduced-intensity
stem cell transplantation; GVHD, graft-versus-host disease;
MTX, methotrexate; PBSC, peripheral blood stem cells; HLA,
human leukocyte antigen.
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the median pretransplant CRP level was 0.3 mg/dL
(range: 0.0-20.5 mg/dL). The median maximum
CRP value during neutropenia was 8.9 mg/dL (0.1-
42.7, Table 2).
Table 2.Comparison of Preengrafment CRP Value Stratified According to
the Conditioning Regimen (CST versus RIST) and the Relation to Donor
(Related versus Unrelated)
Patients’ Characteristics
CRP Value
Median (Range)
All patients 8.9 (0.1-42.7)
CST 10.5 (0.3-31.3)*
Related 9.4 (0.6-30.0)†
Unrelated 10.6 (0.3-31.3)†
RIST 6.2 (0.1-42.7)*
Related 1.6 (0.1-9.7)‡
Unrelated 16.2 (0.5-42.7)‡
CST indicates conventional stem cell transplantation; RIST, re-
duced-intensity stem cell transplantation.
*P 5 .017.
†P 5 .33.
‡P\ .001.The ‘‘maximum CRP level’’ was determined by
measuring both the CRP level and the neutrophil
count, as shown in the example in Figure 1A. The av-
erage number of levels assessed for each patient was 8
(range: 1-30). The median day of the maximum CRP
level was day 10 of HSCT (range: 0-25), with 79%
of patients developing this in later days ($8 days).
The patients were categorized according to the maxi-
mum CRP level after the threshold CRP level was
determined following a preliminary analysis of the
maximum CRP level after CST using an ROC curve
analysis (data not shown). The ‘‘low-CRP’’ group
(CRP \15 mg/dL) included 157 patients and the
‘‘high-CRP’’ group (CRP $15 mg/dL) included 67
patients.
Statistical Analyses
The primary endpoint of this study was the occur-
rence of grade II-IV and grade III-IV aGVHD,
according to the Consensus Criteria [25]. The second-
ary endpoints were overall survival (OS) and nonre-
lapse mortality (NRM). Standard descriptiveFigure 1. An example of how wemeasured CRP in a representative patient (A). Dot plot of the CRP level. All patients (B), CST versus RIST (C)
and related versus unrelated (D).
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act test, and Wilcoxon rank-sum tests were used to
compare clinical and patient characteristics. To ana-
lyze the pretransplant risk factors for a high CRP level,
logistic analysis was used. OS was estimated using Ka-
plan-Meier curves. The cumulative incidence of
aGVHD and NRM was estimated based on a Cox re-
gression model for cause-specific hazards by treating
progressive disease or relapse as a competing event.
Cox proportional hazard models were used for the
multivariate analysis of variables in aGVHD, NRM,
and OS after HSCT. Clinical factors that were as-
sessed for their association with aGVHD included
patient age, patient sex, donor sex, CMV serostatus,
conditioning regimen (CST versus RIST), donor
(human leukocyte antigen [HLA]-matched versus
HLA-mismatched, related versus unrelated), GVHD
prophylaxis (cyclosporine-based versus tacrolimus-
based, short-term MTX versus no MTX) and disease
risk (standard versus high risk). NRM and OS were
also assessed for their association with these factors.
Factors with P\ .10 in the univariate analyses were
subjected to a multivariate analysis using a multiple lo-
gistic analysis and Cox proportional hazard modeling.
In Japan, only BM and CB are allowed for unrelated
transplantation, and most transplantations with a re-
lated donor use PBSC as a stem cell source. Therefore,
the stem cell source was not included as a factor in the
multivariate analysis. A level of P\ .05 was defined as
statistically significant. All P values are 2-sided. All
analyses were made with SPSS ver 10.0 statistical soft-
ware (Chicago, IL). This analysis was approved by the
institutional review board.
RESULTS
Infections
The median duration of follow-up in surviving pa-
tients was 965 days (61 to 1432 days) in the high-CRP
group and 915 days (76 to 1803 days) in the low-CRP
group, and the incidence of total documented infec-
tions during neutropenia was, respectively, 23 cases
in the high-CRP group (34%) and 27 cases in the
low-CRP group (17%, P 5 .004). The incidence of
bacteremia was, respectively, 20 cases (30%) and 20
cases (13%, P5 .002), and the incidence of pneumonia
was 7 cases (10%) and 4 cases (3%, P 5 .01). The in-
cidence of central venous catheter infection was, re-
spectively, 4 cases (6%) and 7 cases (4%, P 5 .63).
Serial changes in the CRP level are shown in
Figure 1B; in most cases, the CRP level was elevated
within 2 weeks of HSCT. Stratified data according
to conditioning regimen (CST versus RIST) or rela-
tion to donor (related versus unrelated) are shown in
Figure 1C and D, respectively.
To clarify the pretransplant risk factors for high
CRP values during neutropenia, we performed a logis-tic regression analysis, which showed that male, unre-
lated donor, stem cell source with BM or CB
transplantation (versus PBSCT), HLA-mismatched
donor, and immunosuppression with MTX were asso-
ciated with high CRP values during neutropenia (Ta-
ble 1). Factors that showed significant associations (P
\ .1) were subjected to a multiple logistic regression
analysis, and the results showed that unrelated donor,
HLAmismatch andmale sex were associated with high
CRP (P\ .001, P 5 .005, P 5 .028, respectively), as
shown in Table 3. The median CRP levels after CST
and RIST were 10.5 (0.3-31.3) and 6.2 (0.1-42.7), re-
spectively, with a significant difference (P5 .017) (Ta-
ble 2). Notably, within the RIST group, the median
CRP level was significantly lower in related than in un-
related transplantation (1.6 mg/dL [0.1-9.7] veruss
16.2 mg/dL [0.5-42.7]: P\ .001). However, the logis-
tic analysis failed to disclose any overall significant dif-
ference between CST and RIST.
Primary Outcomes
The cumulative incidences of aGVHDgrade II-IV
and grade III-IV are shown, respectively, in Figure 2A
and B. Grade II-IV and grade III-IV aGVHD were
both more frequent in the high-CRP group than in
the low-CRP group (P 5 .001 and P 5 .04, respec-
tively). A Cox proportional hazard model showed
that a high CRP level and CMV serostatus were asso-
ciated with an increased risk of grade II-IV aGVHD
(Table 4). Similar results were obtained when we
included only the patientswho received amyeloablative
conditioning regimen (grade II-IV aGVHD 25% in
the low-CRP group and 58% in the high-CRP group,
P\ .001, grade III-IV aGVHD 7% in the low-CRP
group and 21% in the high-CRP group, P 5 .047).
Secondary Outcomes
OS and NRM are shown, respectively, in
Figure 3A and B. OS was significantly worse in the
Table 3. Multiple Logistic Regression Analysis of Risk Factors for High
CRP during Neutropenia
Factors with P\ .10 in a Multivariate Analysis Was Shown*
Multiple Logistic
Regression Analysis
Outcomes and
Variables Odds 95% CI P Value
Unrelated donor 4.6 2.2-9.6 \.001
HLA mismatch 2.6 1.3-5.0 .005
Patient sex (male) 2.1 1.1-4.2 .0028
CRP indicates C-reactive protein; CI, confidence interval; HLA,
human leukocyte antigen; CMV, cytomegalovirus.
*Factors included in univariate analysis: patient sex, donor sex, CMV
serostatus, use of short-term MTX, relation to donor, HLA mis-
match, conditioning, GVHD prophylaxis, stem cell source.
514 S. Fuji et al.Figure 2. Cumulative incidence of grade II-IV aGVHD (A) and grade III-IV aGVHD (B) stratified according to the maximal CRP level during
neutropenia.high-CRP group than in the low-CRP group (1-year
OS 47% versus 75%, P 5 .001). NRM was signifi-
cantly higher in the high-CRP group than in the
low-CRP group (1-year NRM 47% versus 13%, P\
.001). Similar results were obtained when we included
only patients who received a myeloablative condition-
ing regimen (1-year NRM 8% in the low-CRP group
and 38% in the high-CRP group, P 5 .007). A Cox
proportional hazardmodel showed that the risk factors
for poor OS were high CRP (P 5 .002, hazard ratio
[HR] 2.0, 95% confidence interval [CI] 1.3-3.1) and
high-risk disease (P 5 .015, HR 2.2, 95% CI 1.2-
4.0), whereas those for high NRM were high CRP (P
\ .001, HR 4.0, 95% CI 2.0-8.0) and high-risk disease
(P5 .029, HR 2.6, 95%CI 1.1-6.2), as shown in Table
4. When the threshold was set at 15 mg/dL, the sensi-
tivity and specificity of the CRP level for prediction of
grade II-IV aGVHD, NRM, or OS were 37% and
75%, 59% and 79%, and 40% and 78%, respectively.
The relapse rate was significantly lower in the high-
CRP group than in the low-CRP group (1-year relapse
21% versus 33%, P 5 .02).
Causes of death are summarized in Table 5. A total
of 57 patients (36%) in the low-CRP group and 39 pa-
tients (58%) in the high-CRP group died (P 5 .002,
OR 2.4 [1.4-4.4]). Six patients (4%) in the low- and 5
(7%) in the high-CRP group died because of aGVHD,
for example, death because of infectious diseases asso-
ciated with aGVHD and its treatment. Seven patients
(4%) in the low- and 11 (16%) in the high-CRP group
(P 5 .003, OR 4.2 [1.6-11.4]) died because of chronic
GVHD (cGVHD), including death because of infec-
tious diseases associated with cGVHD and its treat-
ment. No patient (0%) in the low- and 5 (7%) in the
high-CRP group (P5 .002) died because of infectious
diseases excluding infectious disease concomitant with
GVHD. No patient in the low-CRP group and 4 (6%)
in the high-CRP group (P5 .008) died because ofmul-
tiple-organ failure (MOF) excluding MOF because of
GVHD and infectious disease.DISCUSSION
The results of this retrospective study suggested
that higher CRP values during the neutropenic period
may reflect net inflammation secondary to tissue dam-
age because of the conditioning regimen, infection,
and subsequent allogeneic immune reactions, all of
which lead to aGVHD/cGVHD and ultimate NRM.
In a mouse model, the concept that the production
of inflammatory cytokines plays an important role in
the development of aGVHD, by affecting the afferent
and effector phase [12,13], has been accepted. Cooke
et al. [26] showed that LPS antagonism reduced
aGVHD in a mouse model, as indicated by Ferrara
et al. [4]. However, in human studies, the value of de-
termining individual levels of cytokines to monitor
aGVHD has not been fully explored, because this ap-
proach is very costly and requires sophisticated tech-
niques, which impedes its universal applicability. On
the other hand, CRP is already being widely used
Table 4. Multiple Variate Analysis for aGVHD, NRM, and OS*
Outcomes and Variables Hazard Ratio 95% CI P value
Grade II-IV aGVHD
High CRP 1.7 1.1-2.6 .02
CMV positivity 3.1 1.0-9.8 .5
Disease risk (high) 1.6 0.9-2.7 .10
NRM
High CRP 4.0 2.0-8.0 \.001
Age ($40 years old) 1.9 0.9-3.9 .07
Disease risk (high) 2.6 1.1-6.2 .03
OS
High CRP 2.0 1.3-3.1 .002
Disease risk (high) 2.2 1.2-4.0 .02
CRP indicates C-reactive protein; CI, confidence interval; CMV,
cytomegalovirus; GVHD, graft-versus -host disease; TBI, total
body irradiation; NRM, nonrelapse mortality; OS, overall
*Factors included in univariate analysis: patient sex, donor sex, CMV
serostatus, use of short-term MTX, relation to donor, HLA mis-
match, conditioning, GVHD prophylaxis, stem cell source
Preengraftment CRP Level and GVHD/Mortality 515Figure 3. OS stratified according to the maximal CRP level during neutropenia (A). Cumulative incidence of TRM stratified according to the
maximal CRP level during neutropenia (B).worldwide, especially in Japan, to distinguish bacterial
infections from other causes of fever [15-19]. Based on
this practice, we reviewed the value of the CRP level
after HSCT, and our data suggest that it might be use-
ful to monitor the CRP value as a net surrogate marker
for produced cytokines, and for predicting the subse-
quent development of aGVHD and NRM.
Our patients had various interacting backgrounds,
and it is still difficult to predict whether a patient with
a high CRP level is destined to suffer from GVHD or
major infectious complications. Infectious diseases
were previously reported to be a primary cause of ele-
vated CRP [8,20], which might, in turn, affect the se-
verity of aGVHD. In this study, we made every
effort, including intense culture studies, to exclude in-
fection as a primary cause of increased CRP, and
showed that there were significantly more documentedinfections in the high-CRP group than in the low-CRP
group. Current practice for the prevention of infection
mostly focuses on the effective control of Gram-nega-
tive bacteria, considering the potent immediate patho-
logic effect of the organisms. However, if the
hypothesis that decreasing the net production of cyto-
kines is important for the prevention of subsequent
GVHD is correct, more effort should be paid to
broadly cover other types of organisms or even clini-
cally less significant infection, that is, stomatitis, at
least during the early period of neutropenia, particu-
larly in patients carrying risk factors for high CRP,
which included unrelated donor, HLA mismatch,
BM, and CB transplantation in this study. The addi-
tion of other markers, such as procalcitonin, may be
useful for identifying the risk of major infectious com-
plications [24].Table 5. Causes of Death Stratified According to CRP Value during Neutropenia
Causes of death
Low CRP Group
CRP\ 15 mg/dL
n 5 157
High CRP Group
CRP $ 15 mg/dL
n 5 67 P Value
Total 57 (36%) 39 (58%) .002
Relapse/progressive disease 34 (22%) 8 (12%) .09
acute GVHD (total) 6 (4%) 5 (7%) .25
acute GVHD 5 (3%) 3 (5%) .63
acute GVHD 1 infection 1 (1%) 2 (3%) .16
chronic GVHD (total) 7 (4%) 11 (16%) .003
chronic GVHD 3 (2%) 7 (10%) .005
chronic GVHD 1 infection 4 (3%) 4 (6%) .21
Infection* 0 (0%) 5 (7%) .002
MOF† 0 (0%) 4 (6%) .008
Respiratory failure‡ 3 (2%) 4 (6%) .11
Others Stroke 2 VOD 1
VOD 2 Myocardial infarction 1
Secondary cancer 1
Unknown 2
CRP indicates C-reactive protein; GVHD, graft-versus-host disease; TBI, total-body irradiation; MOF, multiple organ failure; VOD, veno-
occlusive disease.
*Excluding infection during GVHD or GVHD treatment.
†Excluding MOF due to GVHD, infection.
‡Excluding respiratory failure because of GVHD, infection, and MOF.
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men, complicated infections, and allogeneic immune
reactions are the primary factors that are associated
with the initial elevation of CRP early in the course
of allogeneic HSCT. Consequently, it can be specu-
lated that a reduced-intensity conditioning regimen
results in decreased cytokine release and a resultant
lower CRP value, which may lead to less chance of de-
veloping GVHD. Although the RIST regimens we
used were relatively dose-intense, in this retrospective
review we still found that CRP levels tended to be de-
creased after RIST compared to conventional myeloa-
blative transplantation, particularly in a related
compared to an unrelated transplantation setting. Be-
cause augmentation of allogeneic immune and inflam-
mation reactions may induce a higher CRP value, we
speculate that the benefit of RIST is diminished
when a strong allogeneic reaction is induced, as in
cases of unrelated transplantation.
To further evaluate the relationship between
a higher CRP value during neutropenia and common
risk factors associated with transplantation, we per-
formed a multivariate analysis and showed that unre-
lated donor, HLA mismatch, and male sex were
associated with higher CRP values. Additionally, from
the finding in the multivariate analysis that unrelated
donor and HLA mismatch were independently associ-
ated with highCRP, we surmised that the degree of ge-
netic disparity might be associated with higher CRP
during neutropenia. Based on a consideration of these
findings together, we think that a higher CRP value
may reflect the degree of tissue damage because of the
transplant regimen and the subsequentmagnitude of al-
logeneic immune reactions. Nevertheless, our analysis
was hampered, because in Japan onlyBMandCBare al-
lowed for unrelated transplantations, and most trans-
plantations with a related donor use PBSC as a stem
cell source. In these settings, a theoretically longer neu-
tropenic period after unrelated BM or CB transplanta-
tion might be associated with a higher risk of infection,
which could lead to higher CRP, as shown in this study.
In this study, the primary causes of death in the
low-CRP group were mainly relapse and progression,
whereas in the high-CRP group this was NRM. Nota-
bly, the observation that the relapse rate was higher in
the low-CRP group than in the high-CRP group, as
previously suggested by Min et al. [23], may further
support our hypothesis that serum CRP values repre-
sent overall inflammation and cytokine production,
which paves the way to GVHD and related graft-ver-
sus-leukemia (GVL) effects. A possible reason for
this finding is that a low CRP level resulted in a lower
incidence of GVHD and a resultant decrease in the
GVL effect, or the high-CRP group developed earlier
and more-frequent death from NRM compared to the
low-CRP group, which left fewer patients for evalua-
tion of the later occurrence of relapse.In conclusion, our results suggest that the CRP
value in the neutropenic period before engraftment
in patients undergoing allogeneic HSCT may be
a net surrogate marker of early inflammation that leads
to the development of aGVHD/cGVHD and subse-
quent NRM, as has been proposed in mouse models.
The intensity of the conditioning regimen, infectious
diseases, and degree of allogeneic immune response at-
tributed toHLA compatibility and the stem cell source
may be the major factors that predict higher CRP
values. Based on the results of this retrospective study,
future clinical studies to evaluate the feasibility of ear-
lier intervention and adjustment of the procedure for
preventing GVHD and NRM based on monitoring
of the early CRP value are warranted.
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